Loading
Healthy / Obesity & Overweight / Impaired Fasting Glucose (IFG) · Observational Study
ClinicalTrials.gov · August 6, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a planned observational study registered at ClinicalTrials.gov to investigate beta-cell function response to recombinant human growth hormone in people with impaired fasting glucose or impaired glucose tolerance. No results are yet available from this registry record. The study is still in recruitment planning and cannot inform clinical practice until completion and publication.
Observational. Healthy, Obesity & Overweight, Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (Prediabetes); age from 18 Years; to 59 Years; accepts healthy volunteers. Intervention: Impaired fasting glucose; Impaired glucose tolerance. n = 10. 1 site: United States.
This is a planned observational study registered at ClinicalTrials.gov to investigate beta-cell function response to recombinant human growth hormone in people with impaired fasting glucose or impaired glucose tolerance. No results are yet available from this registry record. The study is still in recruitment planning and cannot inform clinical practice until completion and publication.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
This is a clinical trial registry record describing a planned observational study with no results yet reported; it can only characterize the study design and intended enrollment.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07581860). This is a study registration, not published results. Lead sponsor: University of Missouri-Columbia. Recruitment status: NOT_YET_RECRUITING. Study type: OBSERVATIONAL. Enrollment: 10 participants (ESTIMATED). Conditions: Healthy, Obesity & Overweight, Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (Prediabetes). Primary outcome measures: Beta-cell function , before and 7 days after rhGH administration. Brief summary: The purpose of the research study is to better understand how beta-cells (cells in the pancreas that make insulin and help regulate blood sugar) respond to growth hormone in people with impaired fasting glucose or impaired glucose tolerance at the University of Missouri. The aim of the study is to advance understanding of how growth hormone affects beta-cells and risk factors for developing type 2 diabetes.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.